Baek‐Yeol Ryoo

17.3k total citations · 6 hit papers
349 papers, 10.1k citations indexed

About

Baek‐Yeol Ryoo is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Hepatology. According to data from OpenAlex, Baek‐Yeol Ryoo has authored 349 papers receiving a total of 10.1k indexed citations (citations by other indexed papers that have themselves been cited), including 192 papers in Oncology, 159 papers in Pulmonary and Respiratory Medicine and 110 papers in Hepatology. Recurrent topics in Baek‐Yeol Ryoo's work include Hepatocellular Carcinoma Treatment and Prognosis (108 papers), Gastric Cancer Management and Outcomes (78 papers) and Pancreatic and Hepatic Oncology Research (70 papers). Baek‐Yeol Ryoo is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (108 papers), Gastric Cancer Management and Outcomes (78 papers) and Pancreatic and Hepatic Oncology Research (70 papers). Baek‐Yeol Ryoo collaborates with scholars based in South Korea, United States and Taiwan. Baek‐Yeol Ryoo's co-authors include Yoon‐Koo Kang, Min‐Hee Ryu, Changhoon Yoo, Andrew X. Zhu, Masatoshi Kudo, Ann‐Lii Cheng, Ho Yeong Lim, Richard S. Finn, Thomas Yau and Han Chu Lee and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Baek‐Yeol Ryoo

342 papers receiving 10.0k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial

2019 1.3k citations Richard S. Finn, Baek‐Yeol Ryoo et al. Journal of Clinical Oncology profile →
Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial

2015 634 citations Andrew X. Zhu, Joon Oh Park et al. profile →
Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma

2022 342 citations Andrew X. Zhu, Baek‐Yeol Ryoo et al. Nature Medicine profile →
Efficacy and Safety of Transarterial Chemoembolization Plus External Beam Radiotherapy vs Sorafenib in Hepatocellular Carcinoma With Macroscopic Vascular Invasion

2018 290 citations Baek‐Yeol Ryoo, So Jung Lee et al. profile →
Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial

2022 127 citations Shukui Qin, Zhendong Chen et al. Journal of Clinical Oncology profile →
Tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS-Liver): a randomised, open-label, phase 1b–2, study

2025 26 citations Baek‐Yeol Ryoo et al. profile →

Peers

Countries citing papers authored by Baek‐Yeol Ryoo

Since Specialization

Citations

This map shows the geographic impact of Baek‐Yeol Ryoo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Baek‐Yeol Ryoo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Baek‐Yeol Ryoo more than expected).

Fields of papers citing papers by Baek‐Yeol Ryoo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Baek‐Yeol Ryoo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Baek‐Yeol Ryoo. The network helps show where Baek‐Yeol Ryoo may publish in the future.

Co-authorship network of co-authors of Baek‐Yeol Ryoo

This figure shows the co-authorship network connecting the top 25 collaborators of Baek‐Yeol Ryoo. A scholar is included among the top collaborators of Baek‐Yeol Ryoo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Baek‐Yeol Ryoo. Baek‐Yeol Ryoo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Multicenter single-arm phase II trial of lenvatinib in patients with advanced hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab 2025 ·Journal of Hepatology ·Hyung‐Don Kim, Sun Jin Sym, Hong Jae Chon, (unknown), Jung Hun Kang, Baek‐Yeol Ryoo, Choong‐kun Lee, Joo-Hyun Hong, Hyewon Ryu, (unknown), Hyeyeong Kim, Hyunho Kim, Jin Won Kim, Tae‐Yong Kim, Changhoon Yoo	3
2	Association between beta-catenin (CTNNB1) mutations and clinical outcomes of pembrolizumab in advanced hepatocellular carcinoma (aHCC): Exploratory analyses from KEYNOTE-240. 2024 ·Journal of Clinical Oncology ·Masatoshi Kudo, Ann‐Lii Cheng, Philippe Merle, Baek‐Yeol Ryoo, Thomas Decaens, İrfan Çiçin, Olav Dajani, Raed Moh’d Taiseer Al-Rajabi, Jean‐Marie Péron, Stephen L. Chan, Jennifer J. Knox, (unknown), (unknown), Andrea L. Webber, Carol E. Peña, Răzvan Cristescu, Cai Chen, Ken Hatogai, Abby B. Siegel, Richard S. Finn	1
3	Regorafenib plus nivolumab in unresectable hepatocellular carcinoma: the phase 2 RENOBATE trial 2024 ·Nature Medicine ·Hyung‐Don Kim, (unknown), Ho Yeong Lim, Baek‐Yeol Ryoo, Min‐Hee Ryu, (unknown), Hong Jae Chon, Beodeul Kang, Jung Yong Hong, Han Chu Lee, Deok‐Bog Moon, Ki‐Hun Kim, Tae Won Kim, David Tai, Valerie Chew, Jeong Seok Lee, Richard S. Finn, June‐Young Koh, Changhoon Yoo	29
4	Efficacy and safety of bintrafusp alfa in 2 phase I expansion cohorts with advanced HCC 2024 ·Hepatology ·Ho Yeong Lim, Jeong Heo, (unknown), Baek‐Yeol Ryoo, Thomas Decaens, Fabrice Barlési, Markus Moehler, (unknown), S. Peter Eggleton, Marcis Bajars, James L. Gulley	4
5	Sorafenib for 9,923 Patients with Hepatocellular Carcinoma: An Analysis from National Health Insurance Claim Data in South Korea 2023 ·Gut and Liver ·(unknown), Do Young Kim, Ho Yeong Lim, Jung‐Hwan Yoon, Baek‐Yeol Ryoo, (unknown), (unknown), (unknown), (unknown), Dong‐Sook Kim, (unknown), (unknown), (unknown), Joong‐Won Park	1
6	Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial breakdown → 2022 ·Journal of Clinical Oncology ·Shukui Qin, Zhendong Chen, Weijia Fang, Zhenggang Ren, Ruocai Xu, Baek‐Yeol Ryoo, Zhiqiang Meng, Yuxian Bai, Xiaohong Chen, Xiufeng Liu, Juxiang Xiao, Gwo Fuang Ho, Yimin Mao, Xin Wang, Jieer Ying, Jianfeng Li, Wenyan Zhong, Yu Zhou, Abby B. Siegel, Chunyi Hao	127
7	Clinical Outcomes with Multikinase Inhibitors after Progression on First-Line Atezolizumab plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma: A Multinational Multicenter Retrospective Study 2021 ·Liver Cancer ·Changhoon Yoo, Jwa Hoon Kim, Min‐Hee Ryu, Sook Ryun Park, Danbi Lee, Kang Mo Kim, Ju Hyun Shim, Young‐Suk Lim, Han Chu Lee, Joycelyn Jie Xin Lee, David Tai, Stephen L. Chan, Baek‐Yeol Ryoo	68
8	Kinetics of the neutrophil‐lymphocyte ratio during PD‐1 inhibition as a prognostic factor in advanced hepatocellular carcinoma 2021 ·Liver International ·Won‐Mook Choi, Ji Yoon Kim, Jonggi Choi, Danbi Lee, Ju Hyun Shim, Young‐Suk Lim, Han Chu Lee, Changhoon Yoo, Min‐Hee Ryu, Baek‐Yeol Ryoo, Kang Mo Kim	28
9	Outcomes Based on Plasma Biomarkers for the Phase 3 CELESTIAL Trial of Cabozantinib versus Placebo in Advanced Hepatocellular Carcinoma 2021 ·Liver Cancer ·Lorenza Rimassa, Robin Kate Kelley, Tim Meyer, Baek‐Yeol Ryoo, Philippe Merle, Joong‐Won Park, Jean‐Frédéric Blanc, Ho Yeong Lim, Albert Tran, Yi‐Wah Chan, Paul R. McAdam, Evelyn N. Wang, Ann‐Lii Cheng, Anthony B. El-Khoueiry, Ghassan K. Abou‐Alfa	22
10	Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA) 2021 ·Journal of Clinical Oncology ·J. Randolph Hecht, Sara Lonardi, Johanna C. Bendell, Hao‐Wen Sim, Teresa Macarulla, Charles D. Lopez, Eric Van Cutsem, Andrés J. Muñoz Martín, Joon Oh Park, Richard Greil, Hong Wang, Rebecca R. Hozak, Ivelina Gueorguieva, Yong Lin, Sujata Rao, Baek‐Yeol Ryoo	78
11	Regorafenib in patients with advanced Child‐Pugh B hepatocellular carcinoma: A multicentre retrospective study 2020 ·Liver International ·Hyung‐Don Kim, (unknown), Myung Ah Lee, Jin Won Kim, Jee Hyun Kim, Hong Jae Chon, Beodeul Kang, Myoung Joo Kang, Il Hwan Kim, Jaekyung Cheon, Jun‐Eul Hwang, Jung Hun Kang, Seonggyu Byeon, Jung Yong Hong, Baek‐Yeol Ryoo, Ho Yeong Lim, Changhoon Yoo	34
12	Regorafenib in previously treated advanced hepatocellular carcinoma: Impact of prior immunotherapy and adverse events 2020 ·Liver International ·Changhoon Yoo, Seonggyu Byeon, (unknown), Jaekyung Cheon, Jin W. Kim, Jeeho Kim, Hong Jae Chon, Beodeul Kang, Myoung Joo Kang, Il Hwan Kim, Jun‐Eul Hwang, Jung Hun Kang, Myung A. Lee, Jung Yong Hong, Ho Yeong Lim, Baek‐Yeol Ryoo	31
13	Regorafenib Versus Nivolumab After Sorafenib Failure: Real‐World Data in Patients With Hepatocellular Carcinoma 2020 ·Hepatology Communications ·Won‐Mook Choi, Jonggi Choi, Danbi Lee, Ju Hyun Shim, Young‐Suk Lim, Han Chu Lee, Young‐Hwa Chung, (unknown), Sook Ryun Park, Min‐Hee Ryu, Baek‐Yeol Ryoo, So Jung Lee, Kang Mo Kim	35
14	Health‐related quality‐of‐life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYNOTE‐240 2020 ·Cancer ·Baek‐Yeol Ryoo, Philippe Merle, Amit S. Kulkarni, Ann‐Lii Cheng, Mohamed Bouattour, Ho Yeong Lim, В. В. Бредер, Julien Edeline, Yee Chao, Sadahisa Ogasawara, Thomas Yau, Marcelo Garrido, Stephen L. Chan, Bruno Daniele, Josephine M. Norquist, Erluo Chen, Abby B. Siegel, Andrew X. Zhu, Richard S. Finn, Masatoshi Kudo	25
15	Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial breakdown → 2019 ·Journal of Clinical Oncology ·Richard S. Finn, Baek‐Yeol Ryoo, Philippe Merle, Masatoshi Kudo, Mohamed Bouattour, Ho Yeong Lim, В. В. Бредер, Julien Edeline, Yee Chao, Sadahisa Ogasawara, Thomas Yau, Marcelo Garrido, Stephen L. Chan, Jennifer J. Knox, Bruno Daniele, Scot Ebbinghaus, Erluo Chen, Abby B. Siegel, Andrew X. Zhu, Ann‐Lii Cheng, (unknown)	1300
16	Clinical Outcomes of Conversion Surgery after Neoadjuvant Chemotherapy in Patients with Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer: A Single-Center, Retrospective Analysis 2019 ·Cancers ·Changhoon Yoo, Sang Hyun Shin, Kyu‐pyo Kim, Jae Ho Jeong, Heung-Moon Chang, Jun Kang, Sang Soo Lee, Do Hyun Park, Tae Jun Song, Dong Wan Seo, Sung Koo Lee, Myung‐Hwan Kim, Jin‐hong Park, Dae Wook Hwang, Ki Byung Song, Jae Hoon Lee, Baek‐Yeol Ryoo, Song Cheol Kim	34
17	Assessment of tumor response, alpha-fetoprotein (AFP) response, and time to progression (TTP) in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC) 2018 ·Annals of Oncology ·Thomas Yau, Philippe Merle, Lorenza Rimassa, Baek‐Yeol Ryoo, (unknown), William Proctor Harris, Eugéniu Banu, Debashis Sarker, Benjamin Tan, Hans Van Vlierberghe, Seema Sen, (unknown), Ann‐Lii Cheng, T Meyer, Robin Kate Kelley, Ghassan K. Abou‐Alfa	4
18	Cross-Sectional Study of Imatinib Plasma Trough Levels in Patients With Advanced Gastrointestinal Stromal Tumors: Impact of Gastrointestinal Resection on Exposure to Imatinib 2010 ·Journal of Clinical Oncology ·Changhoon Yoo, Min‐Hee Ryu, Byung Woog Kang, Shinkyo Yoon, Baek‐Yeol Ryoo, Heung-Moon Chang, Jae‐Lyun Lee, (unknown), (unknown), Yoon‐Koo Kang	73
19	The Role of MET Activation in Determining the Sensitivity to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors 2009 ·Molecular Cancer Research ·Jin Kyung Rho, Yun Jung Choi, Jin Kyung Lee, Baek‐Yeol Ryoo, Im Il Na, Sung Hyun Yang, Seung‐Sook Lee, Cheol Hyeon Kim, Young Yoo, Jae Cheol Lee	55
20	p53 Enhances Gefitinib-Induced Growth Inhibition and Apoptosis by Regulation of Fas in Non–Small Cell Lung Cancer 2007 ·Cancer Research ·Jin Kyung Rho, Yun Jung Choi, Baek‐Yeol Ryoo, (unknown), Sung Hyun Yang, Cheol Hyeon Kim, Jae Cheol Lee	96

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact